The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Multicenter phase I/II study of abemaciclib and ramucirumab in metastatic gastroesophageal adenocarcinoma (GEA): CDK4/6 and cyclin D1 alterations as a predictor of response and survival.
 
Ronan Kelly
Honoraria - Cardinal Health
Consulting or Advisory Role - Amgen; Aptitude Health; Astellas Pharma; AstraZeneca; BeiGene; Bristol-Myers Squibb; Clinical Education Alliance; Daiichi Sanyo; Eisai; Exact Sciences; Gilead Sciences; Jazz Pharmaceuticals; Medical Learning Group; Merck; MJH Life Sciences; Novocure; Onc Live; Oncohost; Peerview; Targeted Oncology; Toray Industries
Speakers' Bureau - Astellas Pharma; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Merck
Research Funding - Bristol-Myers Squibb (Inst); Lilly (Inst)
Expert Testimony - Bristol-Myers Squibb
Travel, Accommodations, Expenses - bristol-myers squibb
 
Vincent Lam
Consulting or Advisory Role - Anheart Therapeutics; AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Guardant Health; Iovance Biotherapeutics; Nuvectis Pharma; Pfizer; Takeda
Research Funding - AstraZeneca (Inst); BioNTech SE (Inst); BMS (Inst); Merck (Inst); Nuvalent, Inc. (Inst); Seagen (Inst)
 
Andrew Paulson
Employment - Day One Biopharmaceuticals (I)
Stock and Other Ownership Interests - Actinium Pharmaceuticals
Honoraria - Array BioPharma; Cardinal Health; Curio Science
Consulting or Advisory Role - AADi; Advanced Accelerator Applications; Agenus; Amgen; Array BioPharma; Astellas Pharma; AstraZeneca; Bayer; Bristol Myers Squibb; Eisai; EMD Serono; EMD Serono; Exelixis; Exelixis; Exelixis; Hutchison MediPharma; Incyte; Ipsen; Jazz Pharmaceuticals; Lilly; Mirati Therapeutics; Novartis; Pfizer; QED Therapeutics; Seagen; SERVIER; Stromatis Pharma; Takeda
Speakers' Bureau - Ideo Oncology
Research Funding - AstraZeneca (Inst); Bayer (Inst); BioNTech SE (Inst); bristol myers squibb (Inst); Buzzard Pharmaceuticals; Camurus (Inst); Camurus (Inst); Deciphera (Inst); Exelixis (Inst); G1 Therapeutics (Inst); Gilead Sciences (Inst); Gritstone Bio (Inst); Hutchison MediPharma (Inst); incyte (Inst); Innovative Cellular Therapeutics Co (Inst); Inspirna (Inst); Ipsen (Inst); ITM Oncologics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Nucana (Inst); Regenxbio (Inst); Relay Therapeutics (Inst); Seagen (Inst); Sotio (Inst); Taiho Pharmaceutical (Inst); Tempus (Inst); TransThera Biosciences (Inst); Zentalis (Inst)
Travel, Accommodations, Expenses - AADi; Camurus; Mirati Therapeutics; Nucana; Pfizer
 
A. David McCollum
No Relationships to Disclose
 
Benjamin Kitchens
No Relationships to Disclose
 
Laith Abushahin
Research Funding - Celgene (Inst)
 
Christopher Sherry
No Relationships to Disclose
 
Muhammad Anees
No Relationships to Disclose
 
William LaFramboise
Stock and Other Ownership Interests - Prevencio
Patents, Royalties, Other Intellectual Property - Patents associated with the technology utilized by Prevencio.
 
Russell Schwartz
No Relationships to Disclose
 
Arul Goel
No Relationships to Disclose
 
Ping Zheng
No Relationships to Disclose
 
Patrick Wagner
No Relationships to Disclose
 
David Bartlett
Patents, Royalties, Other Intellectual Property - NIH National Center for Advancing Translational Sciences (NCATS); UPMC Hillman Cancer Center/University of Pittsburgh
 
Moses Raj
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb
Speakers' Bureau - Bristol-Myers Squibb
 
Valsamo Anagnostou
Honoraria - Foundation Medicine; Personal Genome Diagnostics
Consulting or Advisory Role - AstraZeneca; NeoGenomics Laboratories
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Delfi Diagnostics (Inst); Personal Genome Diagnostics (Inst)
 
Ali Zaidi
Stock and Other Ownership Interests - Previse; TG Therapeutics
Consulting or Advisory Role - BillionToOne; Delfi Diagnostics; Gilead Sciences; PrognomIQ
Research Funding - BillionToOne; Delfi Diagnostics; Exai Bio; Genece Health; Myriad Genetics; PrognomIQ; Roche/Genentech; Tempus